Drug Profile
LLG 783
Alternative Names: LLG-783Latest Information Update: 15 Mar 2021
Price :
$50
*
At a glance
- Originator Novartis Pharmaceuticals
- Class Cardiovascular therapies; Monoclonal antibodies
- Mechanism of Action LDL receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Intermittent claudication; Peripheral arterial disorders
Most Recent Events
- 15 Mar 2021 No development reported - Phase-II for Intermittent claudication (In the elderly, Treatment-experienced, In adults) in USA, Germany, Taiwan (IV)
- 15 Mar 2021 No development reported - Phase-II for Peripheral arterial disorders (In the elderly, Treatment-experienced, In adults) in USA, Germany, Taiwan (IV)
- 27 Dec 2018 Novartis completes the phase II PAD PoC trial in Intermittent claudication and Peripheral arterial disorders (In adults, In the elderly, Treatment-experienced) in USA, Germany and Taiwan (IV) (NCT03194776)